Yu M Z, Wu L, Zhang J, Wang J S, Wang Y N, Wang Z
Department of Hematology, Benjing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):572-577. doi: 10.3760/cma.j.issn.0253-2727.2023.07.009.
This study aimed to investigate the clinical characteristics of patients diagnosed with primary hemophagocytic lymphohistiocytosis (pHLH) associated with perforin gene deficiency. We retrospectively analyzed the clinical data of 16 pHLH patients associated with perforin gene deficiency at Beijing Friendship Hospital, Capital Medical University, from April 2014 to August 2021. The mutation sites, mutation types, family history, clinical characteristics, and prognosis of the patients were assessed. A total of 16 patients, including ten males and six females, with a median onset age of 17.5 years (range: 4-42 years), were enrolled in this study. Sixteen different mutations were identified, consisting of 11 missense mutations, one nonsense mutation, two frameshift mutations, and two in-frame mutations. All patients harbored at least one deleterious missense mutation, with the most common mutation sites being c.1349C>T (p.T450M) and c.503G>A (p.S168N). Decreased natural killer (NK) cell activity was observed in 11 patients, reduced perforin protein expression in ten patients, concurrent Epstein-Barr virus (EBV) infection at onset in eight patients, a family history in two patients, and central nervous system involvement in four patients. Eleven cases underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), with eight cases surviving. The median survival time of non-transplanted patients was eight months (range: 4-18 months), while that of transplanted patients was reported as "not reached". Emphasizing the diagnosis of pHLH in adults with perforin gene deficiency. In addition, it should be noted that EBV infection can potentially act as a triggering factor in such disease, and allo-HSCT exerts a substantial effect on the prognosis of patients.
本研究旨在探讨诊断为与穿孔素基因缺陷相关的原发性噬血细胞性淋巴组织细胞增生症(pHLH)患者的临床特征。我们回顾性分析了2014年4月至2021年8月在首都医科大学附属北京友谊医院确诊的16例与穿孔素基因缺陷相关的pHLH患者的临床资料。评估了患者的突变位点、突变类型、家族史、临床特征和预后。本研究共纳入16例患者,其中男性10例,女性6例,中位发病年龄为17.5岁(范围:4至42岁)。共鉴定出16种不同的突变,包括11种错义突变、1种无义突变、2种移码突变和2种框内突变。所有患者均至少携带一种有害的错义突变,最常见的突变位点为c.1349C>T(p.T450M)和c.503G>A(p.S168N)。11例患者观察到自然杀伤(NK)细胞活性降低,10例患者穿孔素蛋白表达减少,8例患者发病时合并EB病毒(EBV)感染,2例患者有家族史,4例患者有中枢神经系统受累。11例患者接受了异基因造血干细胞移植(allo-HSCT),8例存活。未移植患者的中位生存时间为8个月(范围:4至18个月),而移植患者的中位生存时间报告为“未达到”。强调对成年穿孔素基因缺陷患者的pHLH诊断。此外,应注意EBV感染可能是此类疾病的触发因素,allo-HSCT对患者预后有显著影响。